Actinium Pharmaceuticals, Inc.
Simbolis: ATNM
AMEX
8.75
USDRinkos kaina šiandien
-5.2530
P/E santykis
0.0000
PEG koeficientas
260.61M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Actinium Pharmaceuticals, Inc. (ATNM) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 334.99 | 76.7 | 108.9 | 77.8 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 9.78 | 1.6 | 2 | 1.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 344.77 | 78.3 | 110.9 | 79.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.78 | 2.9 | 2.9 | 0.6 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | -0.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 13.02 | 3.2 | 3.3 | 0.6 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.account-payables | 32.25 | 8 | 10.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 2.13 | 0.5 | 0.5 | 0.3 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 6.51 | 1.6 | 2.1 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 140 | 35 | 35 | 0 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -106.57 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | -104.46 | -35 | -35 | 0 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 146.51 | 36.6 | 37.1 | 0 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 7.55 | 1.6 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.total-liab | 180.9 | 45.1 | 47.7 | 6.8 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0.11 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.retained-earnings | -1327.08 | -337.6 | -288.8 | -255.7 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1503.86 | 373.9 | 355.2 | 329.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 357.79 | - | - | - | ||||||||||||||||||
Total Investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.total-debt | 8.64 | 2.1 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.net-debt | -326.35 | -74.6 | -106.3 | -77.5 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.47 | 2.2 | 0.4 | -1.5 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 4.23 | 3.8 | 2.8 | 1.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 1.77 | -3.1 | 38.2 | 1.7 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.account-payables | 0.15 | -2.2 | 4.6 | 1.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 1.61 | -1 | 33.6 | 0.5 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 5.72 | -2.2 | -0.4 | 1.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -39.63 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -0.01 | 0 | 0 | -0.1 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 28.61 | 14.9 | 23.2 | 35.3 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 19.08 | 0.3 | 23.1 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 28.87 | 14.9 | 23.1 | 35.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -10.86 | -32.6 | 31.4 | 14.2 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 335.61 | 76.7 | 109.6 | 78.2 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 346.46 | 109.3 | 78.2 | 64 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | -39.63 | -47.3 | 8.6 | -20.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.free-cash-flow | -39.72 | -47.5 | 8.3 | -21 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.08 | 0.1 | 1 | 1.1 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | -0.74 | -0.7 | 0.3 | 0.6 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 37.04 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 12.56 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 49.6 | 51.2 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 50.01 | 52 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.interest-income | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -49.11 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -49.93 | -51.9 | -34.1 | -25 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.55 | 0 | -1.1 | -0.2 | ||||||||||||||||||
income-statement-row.row.net-income | -46.45 | -48.8 | -31.9 | -24.6 |
Dažnai užduodami klausimai
Kas yra Actinium Pharmaceuticals, Inc. (ATNM) bendras turtas?
Actinium Pharmaceuticals, Inc. (ATNM) bendras turtas yra 81445000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 81000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra -9.173.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -1.424.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -573.469.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -616.457.
Kas yra Actinium Pharmaceuticals, Inc. (ATNM) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -48818000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 2113000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 51211000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 84057000.000.